Open AccessExperience of using durvalumab in unresectable stage III non-small cell lung cancer in Irkutsk Region
Author(s) -
D. Yu. Yukalchuk,
Д. М. Пономаренко,
V. V. Dvornichenko,
A. M. Novopashin
Publication year - 2019
Publication title -
medicinskij alfavit
Language(s) - English
Resource type - Journals
eISSN - 2949-2807
pISSN - 2078-5631
DOI - 10.33667/2078-5631-2019-3-28(403)-5-8
Subject(s) - durvalumab , medicine , lung cancer , radiation therapy , stage (stratigraphy) , immunotherapy , oncology , cancer , nivolumab , paleontology , biology
Non-small cell lung cancer (NSCLC) continues be one of the most frequent oncological diseases both in incidence and mortality. Over the past ten years, due to the targeted and immunotherapy, significant success has been achieved in the treatment of metastatic forms NSCLC, but until recently, approaches to the treatment of earlier stages of NSCLC have remained unchanged. So, the standard treatment of locally-advanced unresectable NSCLC remained chemo-radiation (concurrent or sequential). The first study that has demonstrated the possibility of improving treatment results (including long term results) using an innovative approach from combination of durvalumab immunotherapy with chemo-radiation therapy (CRT) as an integrated treatment complex in this category of patients, has become the PACIFIC study. In Russia, durvalum ab was registered in July 2019 for using in patients with locally advanced NSCLC who have not progressed after CRT, so the experience of its administration in real clinical practice is still small. In this article, we summarized our local experience with durvalumab treatment in seven patients and presented more detailed one of the clinical cases. A patient with stage III unresectable NSCLC began receiving durvalumab therapy in October 2018, 2 months after completing a course of sequential CRT. Currently, after 12 months of therapy, the stabilization of the disease persists, the patient continues treatment.